IL-10 is a critical anti-inflammatory cytokine, the deficiency of which leads to spontaneous autoimmunity. However, therapeutically administered or ectopically expressed IL-10 can either suppress or promote disease. Distinct lineage-specific activities may explain the contradictory effects of IL-10. To dissect the T cell-specific response to IL-10 during organ-specific autoimmunity, we generated mice with a selective deletion of IL-10Ra in T cells and analyzed its effects in an autoimmune model, experimental allergic encephalomyelitis (EAE). Surprisingly, the T cell response to IL-10 increased EAE severity. This did not result from altered T cell functional potential; T cell cytokine profile was preserved. IL-10 also diminished the proliferation of T cells in situ within the target organ, an effect that would be expected to restrain disease. However, IL-10 acted cell autonomously to sustain the autoreactive T cells essential for immunopathogenesis, promoting their accumulation and distorting the regulatory and effector T cell balance. Indeed, in chimeric mice and after adoptive transfer, wild type T cells showed a competitive advantage over cells deficient in IL-10Ra. Therefore, T cell specific actions of IL-10 can support autoimmune inflammation, and this appears to result from an overall increase in the long term fitness of pathologic T cells. Lineage-restricted, disease-promoting activities of IL-10 should be considered in the therapeutic manipulation of the IL-10 pathway. The Journal of Immunology, 2012, 189: 000-000. I nterleukin-10 is critical in setting immune response amplitude (1-3). Its genetic ablation or inhibition leads to spontaneous colitis and exacerbation of autoimmune and inflammatory diseases. Polymorphisms in the IL-10 gene or its receptor are associated with autoimmune susceptibility (4, 5) . In infections, IL-10 protects against immunopathology mediated by overly exuberant immune responses. Despite the considerable therapeutic potential of IL-10, immunomodulatory agents that act by manipulating the IL-10 pathway are not currently available.
I nterleukin-10 is critical in setting immune response amplitude (1-3). Its genetic ablation or inhibition leads to spontaneous colitis and exacerbation of autoimmune and inflammatory diseases. Polymorphisms in the IL-10 gene or its receptor are associated with autoimmune susceptibility (4, 5) . In infections, IL-10 protects against immunopathology mediated by overly exuberant immune responses. Despite the considerable therapeutic potential of IL-10, immunomodulatory agents that act by manipulating the IL-10 pathway are not currently available.
Although the anti-inflammatory activities of IL-10 are well established, its actions are not exclusively immunosuppressive. IL-10 promotes B cell growth and differentiation and, by inhibiting apoptosis, tumor cell and lymphocyte survival (6) (7) (8) (9) (10) . Localized overproduction of IL-10 in pancreatic islets in transgenic (Tg) mice leads to islet destruction and diabetes (11) . Its overexpression by tumors can promote either tolerance or rejection (12, 13) . Efficacy of pharmacologically administered IL-10 in experimental allergic encephalomyelitis (EAE) varied with timing and mode of administration, and could even exacerbate disease (14) (15) (16) (17) . Clinical trials of IL-10 failed to show benefit in Crohn disease (18) .
Clarifying the disparate though predominantly anti-inflammatory activities of IL-10, and deciphering how IL-10 might be optimally manipulated for therapy, will require a dissection of its cell typespecific actions in disease states. Although T cells express only low levels of IL-10R, they are potentially an important target. Studies of IL-10Rb-deficient animals can be complicated by the nonexclusive use of this receptor chain by other cytokines, particularly the IFN-ls (19) , but have implicated the T cell response to IL-10 in disease susceptibility (20, 21) . Recent reports have alternatively used mice overexpressing a dominant negative IL-10Ra or conditionally deficient in the leader sequence (exon 1) of IL10Ra (22) (23) (24) . These reports identified a protective role for IL-10 in intestinal inflammation by its selective suppression of pathologic Th17 responses. Studies of CD8 T cell response during infection further indicated a direct role for IL-10 in the acquisition of memory, and therefore in the capacity of T cells to maintain longterm immunity (25) .
In this study, we assess the effects of IL-10 signaling into T cells in a pathophysiologically distinct autoimmune model, EAE. EAE results from immune mediated CNS demyelination orchestrated by self-Ag-specific Th1 and Th17 cells (26) . Naturally produced IL-10 is protective (27) . In prior analyses, we demonstrated that regulatory T lymphocytes specifically retargeted against the autoreactive T cells responsible for EAE were highly effective as a cellular immunotherapeutic. The activity of the regulatory cells was IL-10 dependent, implicating direct actions of IL-10 on T cells in disease abatement (28, 29) .
To better explore the T cell response to IL-10, we developed a new mouse model conditionally deficient in the cytokine-binding domain (exon 3) of IL-10Ra, the IL-10-specific component of the IL-10R. Mice with selective deletion of IL-10Ra on T cells (denoted Tdel ) showed no detectable abnormalities in the absence of disease induction. Paradoxically, Tdel mice demonstrated diminished EAE, indicating that whereas IL-10 overall reduces EAE severity, it acts on T cells to increase their autoimmune potential. Our analyses demonstrate that the absence of IL-10 responsiveness leads to unaltered T subset maturation, but a cell-intrinsic effect of IL-10 on effector T cell (Teff) dynamics during the autoimmune response; IL-10 inhibited autoreactive CD4 T cell expansion while promoting cell persistence. The net result of these contrasting activities was to help sustain the autoreactive T cell response. These results therefore describe a distinct IL-10-mediated program that selectively acts on T cells to promote autoimmunity, highlight the contextual complexity of IL-10 signaling, and provide insight into how cell-specific actions of this globally anti-inflammatory cytokine might enhance an inflammatory disease.
Materials and Methods

IL-10Ra conditionally deficient mice
A 12.6-kb segment incorporating IL-10Ra exon 1-5 was isolated from a C57BL/6-derived bacterial artificial chromosome, and an FLP recombinase target-flanked neo r gene introduced into intron 3 and loxp sites added flanking exon 3 by recombineering (30) (Fig. 1A ). This gene segment was introduced by homologous recombination into the C57BL/6-derived ES26.2 embryonic stem cell line, with correct targeting ascertained by Southern. Embryonic stem cells were injected into C57BL/6J-Tyr
blastocysts to generate recombinant mice. These mice were bred with B6. Cg-Tg(ACTFLPe) 9205Dym/J mice to delete the neo r , leaving the loxp-flanked IL-10Ra exon 3. Exon 3 incorporates much of the IL-10 interacting domain, and its deletion leads to an additional frameshift in downstream sequence.
Mice and reagents
Myelin oligodendrocyte glycoprotein (MOG) 35 
IL-10Ra
Tdel mouse phenotyping and quantitative PCR
To genotype mice, genomic DNA was amplified with primers specific for Cre (59-GGCCCCATGGCATCCAATTTACTGACCGTACAC-39 and 59-TCGCTCGAGGTGATCGCCATCTTCCAGCAG-39), floxed and WT IL-10Ra alleles (59-CTCCATACGAGAGGTCTTGGG-39 and 59-GCTAACTGCCCTGGGACTCCC-39), and GFP (59-TGCCTCTGACAA-GAACCCAATGC-39 and 59-GGCAGGGGGTTCAAGGAAGAAG-39). For quantitative analysis of lineage specific deletion, CD4 T, CD8 T, and B cells were isolated by flow cytometric sorting from IL-10Ra  Tdel and WT  (IL-10Ra fl/fl CD4-Cre 2 ) mice, and genomic DNA isolated. IL-10Ra exon 3 was amplified using forward primer 59-CCGGGCAGTGGACAACA-39 and reverse primer 59-CCACTGTGAAGCGAGTCTCAGT-39 (primer set 1) or forward primer 59-AACCTGGAATGACATCCATATC-39and the same reverse primer (primer set 2) using real-time PCR. Cycle threshold (Ct) data were compared with GAPDH as an internal control, and this was normalized to Ct data from simultaneously analyzed WT CD4 T cells using the comparative Ct approach (2 2DDCt ).
Flow cytometry and cell sorting
Analytic cytometry was performed on a Becton-Dickinson FACSCalibur or LSRII and analyzed with FlowJo software (Tree Star). Sorting was performed with a Mo-Flo (Dako) or Reflection (iCyt) cytometer. Abs targeting CD4, TCRb, CD3, CD11c, CD11b, CD205, CD8, B220, CD45R, Gr-1, F4/ 80, CD5, CD44, CD25, CD19, TCRgd, NK1.1, 45Rb, CD62L, CCR2, CCR5, CD11, CXCR3, VLA-4, CD69, CD45.1, CD45.2, IL-10R, and RatIgG2b were from BD Biosciences. Anti-Thy1.1 and Foxp3 were from eBioscience.
Intracellular staining
For cytokine intracellular staining (ICS), isolated lymphocytes were washed and stimulated with PMA (50 ng/ml) and ionomycin (1 mg/ml) for 4 h in the presence of 10 mg/ml Brefeldin A (Sigma), labeled with CD4 and TCRb Abs, fixed and permeabilized (Fixation Buffer, eBioscience), and then labeled with anti-IFNG, IL-10, and IL-17 Abs. ICS for Foxp3 was performed using the eBioscience Foxp3 staining kit. For phospho-Stat3, d4 activated T cells were stimulated with 10 ng/ml rIL-10 or medium only for 40 min at 37˚C, fixed with 1% formaldehyde for 10 min at 37˚C, washed, permeabilized with ice-cold 90% methanol for 30 min on ice, labeled with anti-P-Stat3 (Y705; Cell Signaling), washed, and stained with F(ab9) 2 goat anti-rabbit IgG (Invitrogen).
EAE induction and clinical evaluation
EAE was induced by s.c. immunization with 100 mg MOG peptide in 100 ml CFA containing 0.4 mg Mycobacterium tuberculosis H37RA (Difco); 200 ng pertussis toxin (List Biological Laboratories) was administered i.v. on days 0 and 2. Clinical scoring was: 1 = limp tail; 2 = hind limb paresis or partial paralysis; 3 = total hind limb paralysis; 4 = hind limb paralysis and body or front limb paresis or paralysis; 5 = moribund.
Histopathology scoring
Euthanized mice were perfused with 10% buffered formalin (Thermo Scientific). Brains and spinal cords left in place within the skull and vertebral columns and postfixed in 10% buffered formalin for .24 h, decalcified in formic acid (TBD-2 Decalcifier; Thermo Scientific), and cut into transverse sections of brain, brainstem, and cervical, thoracic, and lumbar spinal cord. Histopathologic examination of H&E sections were performed in a blinded fashion, with sections evaluated in staggered order. Each histologic lesion (mononuclear perivascular cuffing, gliosis, vacuolization or demyelination of axons, and neutrophilic infiltration) was scored independently according to predetermined criteria: 0 = lesions absent, 1 = minimal inconspicuous lesions, 2 = mild conspicuous lesions, 3 = prominent multifocal moderate lesions, 4 = marked coalescing lesions. For each animal, the individual lesion scores in all regions were totaled to determine an overall EAE severity score.
Cell isolation and enumeration
Mice were sacrificed, lymph nodes (LN) and spleens were removed, the circulation was perfused with 4˚C PBS, and the brains and spinal cords were removed. CNS lymphocytes were isolated by density centrifugation as described (31) , counted on a hemacytometer, and quantitatively analyzed by flow cytometry.
T cell proliferation
Splenic, draining LN, and CNS cells were isolated, and total cells or magnetic bead-isolated CD4 T cells were stimulated as indicated at 5 
In vivo proliferation
Mice were injected i.p. with 150 ml BrdU (10 mg/ml) in sterile 13 DPBS. After 16-20 h, lymphocytes were isolated, stained with Abs to cell surface markers, fixed and permeabilized with Cytofix/Cytoperm Buffer (BD Biosciences), treated with DNase (300 mg/ml) at 37˚C for 1 h, and then stained with anti-BrdU-APC (3D4, BD Biosciences), and analyzed by flow cytometry. 
In vivo Treg depletion
Hematopoietic chimeras and lymphocyte cotransfers
For hematopoietic chimeras, bone marrow cells were obtained from femurs and tibias of WT and IL-10Ra
Tdel mice expressing the indicated congenic markers, washed, and mixed in equal quantities; 10 3 10 6 cells were injected i.v. into lethally irradiated (900 rad) TCRa 2/2 recipients. For lymphocyte cotransfers, single-cell suspensions of erythrocyte-lysed lymph node and splenic cells from WT and IL-10Ra
Tdel mice expressing the indicated congenic markers were prepared. Cells were mixed in approximately equal quantities and injected i.v. into CD45.1 congenic mice.
Statistics
Standard deviations or errors and confidence intervals were calculated with Microsoft Excel or PRISM software. Significance between two groups was calculated with two-tailed t test. When more than two groups were present in an assay, significance was determined with one-way, two-tailed ANOVA using a Bonferroni correction for multiple comparisons. A p value , 0.05 was considered significant. For multiple comparisons, significance is only shown relative to the control group unless otherwise indicated.
Results
Characterization of mice with T cell deficiency in IL-10 response
We generated C57BL/6 mice bearing a floxed IL-10Ra exon 3 (IL-10Ra fl/fl ; Fig. 1A ) and bred these with mice expressing CRE selectively on T cells (CD4-Cre). Sorted IL-10Ra Tdel T but not B cells showed loss of genomic IL-10Ra exon 3 by quantitative PCR (Fig. 1B) . IL-10R expression, measured by surface staining, was absent from IL-10Ra
Tdel T cells, but expressed at WT levels on B cells, macrophage, and dendritic cells (Fig. 1C and data not shown). IL-10 signals through STAT3 (1), and IL-10Ra
Tdel T cell STAT3 phosphorylation was absent to IL-10 ( Fig. 1D) Fig. 1 ). To functionally assess the IL-10Ra (Fig. 1F) . The IL-10Ra
Tdel mice were further bred with GFP-Foxp3 knock-in mice for intravital demarcation of Tregs. Flow cytometrically purified IL-10Ra Tdel and WT Tregs demonstrated equivalent capacity to suppress naive T cell proliferation (Fig. 1G) . Therefore, unmanipulated IL-10Ra
Tdel mice appear normal through clinical observation, gross and histologic analysis, phenotypic characterization, and in vitro functional assessments.
Diminished EAE severity in IL-10Ra
Tdel mice
Considering the documented role of IL-10 in restraining EAE and other forms of autoimmunity, and of T-specific IL-10 in suppressing intestinal inflammation, we anticipated that IL-10Ra
Tdel mice would develop more severe EAE than WT controls. To the contrary, after immunization with MOG , the mice showed consistently less severe disease ( Fig. 2A ). Cumulative and peak disease were decreased in the IL-10Ra Tdel cohorts, although not time to initial disease symptoms (Fig. 2B , Supplemental Table I ). All mortality was in the WT group. Therefore, although globally immunoregulatory, IL-10 acts focally on T cells to promote MOGinduced EAE.
Diminished infiltrates and increased Treg:Teff ratios in IL-10Ra
Pathologically distinct forms of EAE can be distinguished histologically. To determine whether the altered disease severity was associated with an altered immunopathologic process, we reviewed the histopathology of 6 WT and 7 IL-10Ra Tdel mice with diverse disease scores. Forebrain, brain stem, and cervical, thoracic, and lumbar spinal cord were assessed for gliosis, parenchymal vacuolation and demyelination, neutrophil infiltrate, and mononuclear cuffing. Linear regression modeling of histologic scores showed a positive correlation with clinical disease (Fig. 3A-E) . However, slope and intercept for individual parameters and cumulative score did not differ between the WT and IL-10Ra
Tdel CNS. Therefore, WT and IL-10Ra Tdel mice develop a qualitatively similar disease that differs in magnitude of severity.
To quantify differences in the T cell response, CD4 + Teff and Foxp3 + Tregs were enumerated in diseased CNS and spleen 14 and 21 d after induction. At the earlier time point, a significantly increased number of Teff was present in WT compared with IL10Ra
Tdel CNS, consistent with their more severe disease (Fig. 4A ). This increase, however, was not associated with a parallel increase of CNS-infiltrating Tregs, resulting in a diminished Treg:Teff ratio in WT compared with IL-10Ra
Tdel CNS. We and others have demonstrated that Tregs are potently inhibitory in MOG-induced EAE (28, 31, 32) , and the Treg:Teff ratio is a critical indicator of activity. Therefore, T cell response to IL-10 augments early Teff infiltration in the CNS while decreasing the proportion of Tregs.
At day 21, the magnitude of the infiltrate in both WT and IL10Ra
Tdel mice was substantially increased (Fig. 4B ). An increase in both Teff and Treg numbers was evident in WT mice; however, the growth of the Treg population exceeded that of Teff, leading to an increased Treg:Teff ratio compared with day 14. A rapid expansion of CNS Tregs during EAE has been previously described (33) . In IL-10Ra
Tdel mice, infiltrating Teff and Treg numbers were overall decreased relative to WT mice, reflecting their milder disease. The percentage of Tregs was increased relative to day 14; however, the magnitude of this increase was not as pronounced as in the WT mice, and the proportion of Tregs did not significantly differ from WT mice as it had at the earlier time point. Therefore, the kinetics of CNS T cell accumulation differs between WT and IL-10Ra
Tdel mice, with IL-10Ra Tdel mice showing overall Tdel to WT mice is plotted. Mean of values is indicated by the central line, and 95% confidence interval for means is indicated by brackets to the right of this. Additional data are provided in Supplemental Table I .
FIGURE 3. Histologic analysis of CNS in IL-10Ra
Tdel and WT mice with EAE. Forebrains, brain stems, and cervical, thoracic, and lumbar spinal cords from mice 20-22 d after disease induction were blindly assessed and scored for gliosis, parenchymal vacuolation and demyelination, neutrophil infiltrate, and mononuclear cuffing. Cumulative histologic scores across location and parameter (A) or for individual parameters across location (B-E) were tallied and are plotted. Linear regression modeling is overlayed and p values for slope and intercept comparing IL10Ra
Tdel and WT mice are indicated.
decreased total T cell accumulation early and late and an increased proportion of Tregs early in disease.
Similar cytokine profiles and migratory phenotype of WT and IL-10Ra Tdel T cells
A mixed Th1 and Th17 response fosters the development and progression of MOG-induced EAE (26, 34) . Blockade of Th17 differentiation ameliorates disease, and direct actions of IL-10 have been shown to suppress Th17 cells (22, 23 ). An increased Th17 response would have been expected to increase disease severity in IL-10Ra Tdel mice, whereas disease was decreased. Nevertheless, to evaluate for altered Teff subset differentiation, we measured CD4 + T cell cytokine profiles directly by intracytoplasmic staining. Similar proportions of CNS or splenic CD4 + T cells producing IFNG, IL-17, and IL-10 were detected in WT and IL-10Ra Tdel mice ( Fig. 5A-C) . MOG-induced cytokine production, including IL-2, IL-4, IL-10, IFNG, and IL-17, was also similar in WT and IL-10Ra
Tdel T cells (Fig. 5D) . Therefore, the actions of IL-10 on T cells did not detectably skew subset responses during EAE.
As a supplemental explanation for the diminished number of T cells in CNS infiltrates of IL-10Ra
Tdel mice with EAE, we considered the possibility that they had decreased migratory potential. To examine this possibility, levels of CCR2, CCR5, CXCR3, CD11a, and VLA-4, markers associated with T cell CNS migration, were measured on draining LN, splenic, and CNS T cells in mice with EAE (Supplemental Fig. 2 ). No differences were seen between WT and IL-10Ra
Tdel populations. Therefore, defective response to IL-10 does not affect phenotypic markers associated with CNS localization.
Ex vivo IL-10Ra
Tdel T cell proliferation
To further define the role of IL-10 in shaping response magnitude, IL-10Ra Tdel and WT splenocytes were isolated from mice with EAE, stimulated with MOG , and their autoantigen-specific proliferative response measured. At 14 d after disease induction, responses were similar, indicating that an equivalent proportion of T cells was capable of recognizing and being effectively stimulated by Ags (Fig. 5E) . By 21 d, however, the T cell responses diverged, with less proliferation seen among IL-10Ra
Tdel splenocytes (Fig. 5F ). Therefore, the peripheral T cell response to IL-10 varies with time after disease induction. IL-10 helps to sustain the autoantigenspecific response later in disease.
MOG-specific T cells are concentrated in the CNS of mice with EAE. Although fewer T cells were present in the CNS infiltrates of IL-10Ra
Tdel compared with WT mice (Fig. 4) , on a per cell basis, purified CD4 + T cells from WT or IL-10Ra Tdel mice demonstrated Tdel mice. To further examine this, we measured in situ T cell proliferation by BrdU labeling. The decreased absolute T cell numbers in the CNS of IL-10Ra
Tdel mice would be expected to be associated with a decreased proportion of cycling (BrdU + ) cells. In the spleen, only a small proportion of T cells will be MOG specific. At day 14, WT and IL-10Ra
Tdel splenic CD4 + T cells showed similar BrdU incorporation, both for Foxp3 + and Foxp3 2 cells (Fig. 6A, 6B ). Autoantigen-specific cells will, however, concentrate in the CNS. In this study, IL-10Ra Tdel Tregs and Teffs showed significantly increased BrdU uptake compared with WT, indicating that, in contrast with our prediction, these were proliferating more rapidly at the site of autoimmunity. Analysis of total numbers of BrdU + cells in the CNS did not show any difference between IL-10Ra
Tdel and WT mice, either for Teff or Tregs (data not shown). Therefore, despite an early increase in proliferation rate in IL-10Ra
Tdel mice in situ and absolute numbers of proliferating T cells that did not differ compared with WT mice, there is a diminished accumulation of CNS T cells in the IL-10Ra
Tdel mice. By d21, as clinical disease crested, rates of BrdU incorporation were diminished and similar between the two cohorts in both the CNS and spleen (Fig. 6C) . Therefore, in early but not late EAE, CNS-infiltrating IL-10Ra
Tdel Teff and Tregs are cycling more rapidly than WT cells. This increased proliferation is consistent with the documented antiproliferative effects of IL-10 in vitro (35) and after anti-CD3 treatment in vivo (22) , however, is incongruously associated with diminished total CNS IL-10Ra
Tdel Teff numbers and an increased Treg proportion that would be expected to suppress proliferation (Fig. 4) . It is also incongruously associated with the diminished proliferative response to MOG among IL-10Ra
Tdel splenocytes at day 21 in vitro ( Fig. 5F ). + T cells were purified from the CNS of mice with EAE (day 21), and equal numbers were stimulated with no or 100 mg/ml MOG in the presence of irradiated splenic APCs from nonimmune WT mice. Proliferation was measured as above. Mean proliferation of individual mice is plotted. Results were not significantly different for IL-10Ra
Tdel versus WT mice. Data are representative of two or more experiments. **p , 0.01, ***p , 0.001 for IL-10Ra
Tdel versus WT cohorts (F) or unstimulated versus stimulated (G).
Retained IL-10Ra Tdel disease resistance after Treg depletion
One possible explanation for this inconsistency is that the increased proportion of Treg in the IL-10Ra Tdel CNS did not act by limiting Teff proliferation, but instead promoted Teff elimination either directly by cytolysis or indirectly by decreasing overall inflammation. To evaluate the independent effects of IL-10 on Teff cells, we depleted Tregs by treatment with the CD25-specific PC61 Ab prior to EAE induction. Consistent with prior observations (36), PC61 eliminated virtually all CD25 + and most Foxp3 + cells (Supplemental Fig. 3A-C) . As previously described, Treg-depleted mice developed more severe EAE than did mice treated with control Ab (Fig. 7A) ; however, this was similarly true for IL-10Ra Tdel and WT mice. Indeed, IL-10Ra
Tdel mice treated with PC61 demonstrated substantially less severe disease than WT mice treated with even control Ab. Like in Fig. 2 , both cumulative and maximal disease scores were greater in WT than IL-10Ra
Tdel mice (Fig. 7B) . Furthermore, the extent of this increase was similar in PC61 and control Ab-treated cohorts. This finding supports the presence of a Treg-independent effect in governing disease susceptibility.
Competitive analysis of Treg and Teff cell dynamics
To isolate the cell-intrinsic effects of IL-10 on T cells, we competitively analyzed mixed populations of IL-10Ra
Tdel and WT T cells. Because the cells share an identical environment, we could thereby exclude indirect effects of T cell IL-10 signaling that otherwise may influence outcome. We generated chimeric mice in which CD45. Fig. 8A-C) . However, in chimeric mice with symptomatic disease, a significant increase in WT versus IL-10Ra
Tdel Teff cells was Tdel and WT mice from three independent experiments is plotted. Although PC61 treatment led to overall more severe disease, the ratio of each parameter between IL10Ra
Tdel and WT mice was not significantly altered by PC61 treatment.
observed in the CNS. A similar trend was apparent for Tregs, although this did not achieve significance. Foxp3 2 Teff from diseased mice were further segregated into memory or activated (CD44 hi ) and naive (CD44 lo CD62L hi ) populations. The memory or activated populations were selectively skewed toward WT T cells, and this was true in both the spleen and CNS (Fig. 8D) . In contrast, the naive populations showed a WT:IL-10Ra
Tdel ratio similar to that of cells prior to immunization (preimmune blood, 1.2 6 0.4; naive spleen, 1.2 6 0.4; memory spleen, 2.1 6 0.9; naive CNS, 1.4 6 0.7; memory CNS, 2.7 6 1.5). Therefore, activated but not naive WT T cells outcompete corresponding IL-10Ra
Tdel cells in the chimeric mice.
As an alternative approach to verify these findings and competitively evaluate the cell-intrinsic effect of IL-10 on T cell responses, one excluding thymic generation of new T cells, mature WT and IL-10Ra
Tdel cells were mixed and cotransferred into WT recipients. Host and transferred populations could be distinguished by congenic markers (host, CD45. (Fig. 8E,  8F ). This ratio was maintained at day 7. By day 16, after EAE development, a significantly increased proportion of WT T cells was observed in the spleen. A more dramatic increase was evident within the CNS (WT/IL-10Ra
Tdel ratio: preimmune blood day 0, 0.68 6 0.29; day 7 blood, 0.83 6 0.03; day 16 spleen, 1.7 6 0.3; day 16 CNS, 8.7 6 1.2). Skewing of the splenic response toward WT cells was specific to the activated or memory population ( Fig. 8G ; naive day 16, 1.1 6 0.1; memory day 16, 2.3 6 0.4). A corresponding analysis of differential skewing among naive and activated or memory populations was not possible in the CNS because of the paucity of naive T cells at this location (.90% memory) and the small number of transferred cells detected. Nevertheless, these results confirm findings in the bone marrow chimeras and indicate that IL-10 signaling provides a cell-intrinsic competitive advantage to WT Teff cells during EAE.
Discussion
IL-10 controls inflammation, whether infectious, autoimmune, or toxic. Its production, proportionate to the level of inflammation, provides negative feedback against excessive responses (37) . IL-10 lacks recognized proinflammatory activities in T cells. Despite this, we show that IL-10 promotes autoimmune inflammation in EAE. Our data support a cell-intrinsic role for IL-10 in the long- term sustenance of the autoreactive T cells essential to this disease as a mechanism. IL-10 can regulate genes inhibiting cell cycle progression. In accordance with this, we observe that WT T cells proliferate less rapidly than IL-10Ra
Tdel cells in the CNS in vivo. Implicitly, IL-10 is acting to restrain autoreactive T cell expansion. The decreased rate of cell cycling in the WT CNS contrasts with the equivalent proliferation of CNS T cells measured in vitro. This indicates that environmental conditions present in the WT CNS inhibit WT T cell cycling, and that these conditions are not present when T cells are purified and restimulated with Ag and feeder cells in culture. The decreased cell cycling in the CNS of WT mice is also incongruously associated with an increased accumulation of CNS-infiltrating T cells and more severe clinical disease. This cannot be explained solely by the decreased proportion of Tregs seen early in disease in WT mice. IL-10Ra
Tdel mice depleted of Tregs still showed less severe EAE than similarly treated WT mice. More severe disease would be expected if the effects of IL-10 were wholly Treg dependent. Moreover, WT T cells outcompete IL-10Ra
Tdel T cells in mixed chimeras, both bone marrow chimeras and after the cotransfer of mature WT and IL-10Ra Tdel T cells, indicating that the effect of IL-10 on T cell dominance is cell intrinsic. Therefore, IL-10 supports the Teff response in EAE despite its suppression of T cell proliferation in situ, and this is independent of altered Treg quantities or function.
Our data are also inconsistent with IL-10 altering the functional profile of autoreactive T cells. A classical pattern of clinical and histologic disease was seen in the IL-10Ra
Tdel mice. Histologic patterns may be altered by perturbations in T cell profiles (38) . Cytokine production by responding T cells was also unaffected. Likewise, expression of relevant chemokine receptors and addressins failed to differentiate WT and IL-10Ra
Tdel populations, implying that the cells had similar capacity to localize to the inflamed CNS.
The balanced inhibition of T cell subsets in this study contrasts with what has been observed in studies of mucosal immunity in mice bearing T cells expressing a dominant negative IL-10Ra or with a selective deficiency of IL-10Ra on Tregs (22) (23) (24) . In those Tregs, a specific effect on Th17 accumulation was documented. Indeed, we have observed a similar skewing of the IL-10Ra Tdel Th17 response in a model of sepsis (R. Alli and T. Geiger, unpublished observations), indicating a common role for IL-10 in regulating Th17 production. This skewing suggests that the effect of IL-10 on T cells is highly contextual. Indeed, although in vivo data are limited, IL-10 has documented activity against multiple T cell lineages and can directly inhibit Th1 IFNG secretion and Th2 IL-4 and IL-5 production (35, (39) (40) (41) . It can be anticipated that the magnitude and quality of IL-10's effects will depend on the quantity of IL-10 produced as well as the quality and quantity of alternative signaling inputs received by targeted cells. For example, we can speculate that the relatively large amounts of IL-10 constitutively produced in the intestines or during sepsis, by inducing SOCS3, may promote the relatively selective inhibition of IL-6 signaling and Th17 differentiation (42, 43) . In EAE, differential regulation or altered quantities of IL-10 may promote less selective pathways.
That the presence of IL-10 led to the increased accumulation of autoreactive T cells despite their diminished expansion rate indicates that IL-10 helped to sustain the autoreactive T cell population. This is consistent with in vitro data indicating that IL-10 promotes T cell survival with the withdrawal of alternative prosurvival cytokines, and the documented regulation of antiapoptotic genes by IL-10 in other cell types (44, 45) . More recently a role for IL-10 in promoting CD8 T cell memory has been described (25) . Response persistence is fundamental to autoimmunity, and we can speculate that the cytokine environment supporting the long-term maintenance of reactive T cells during autoimmunity may be similar to that promoting the generation of long-lived memory cells. T cells proliferate up to several times per day after stimulation (46) , and even subtle changes in proliferation or survival rates, compounded over time, can dramatically influence cell dominance. Implicitly, the conflicting effects of IL-10 in both inhibiting T cell expansion and promoting their persistence, when integrated over time, determines outcome. Cues that differentially alter IL10's influence on proliferation inhibition and T cell survival may thereby alter the net effect of IL-10 on T cell-mediated immune responses.
Presumably, increased attrition of cells unable to respond to IL-10 results from their apoptotic death. Apoptotic cells are rapidly cleared in vivo, and measuring ongoing rates of apoptosis in situ is technically difficult. Nevertheless, we observed diminished MOG-induced proliferative response among peripheral IL-10Ra
Tdel splenocytes and a selective competitive advantage among memory-activated WT T cells in mixed chimeras, indicating that the autoreactive T cells are not sustained in the absence of T-specific IL-10 responsiveness. Cytokine withdrawal or activation-induced apoptosis would seem the most likely causes. Further breeding of IL-10Ra
Tdel mice onto backgrounds with altered apoptosis susceptibilities will be important to directly evaluate the hypothesis that IL-10 alters cell death rates and to interrogate mechanism.
Global IL-10 deficiency leads to increased EAE severity (27) . That T-specific IL-10 unresponsiveness attenuates disease indicates that the effect of IL-10 on T cells is counterbalanced by more potent activities on other cell types. Indeed, myeloid-derived APCs and effector cells express higher levels of IL-10R than do T cells, and these and the glial population that more directly mediates myelin damage would seem probable IL-10 targets. Dissecting responsible cell types is possible using conditional systems, such as that described here, which were not previously available. Nevertheless, that T cell directed IL-10 has an ultimately pathologic effect does emphasize the importance of directed targeting by therapeutically administered IL-10, and might explain the conflicting results on the efficacy of pharmacologically administered IL-10. Our results argue that it is the balance of opposing effects of IL-10 both within individual cell types, where cell preservation may coincide with decreased proliferation, as well as across lineages that defines ultimate outcome. *** ***
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